Nurses May Be Key to Long-Term Clinical Trial Success

At the end of the study, the vast majority of participants described themselves as satisfied, happy and proud to have finished the study. Many patients also noted that they were relieved the study was over. The authors concluded their paper by suggesting that investigators can cultivate such patient motivators as a sense of contribution to research and possibly retain more patients in long-term studies.

Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

References

Markusse IM, Dirven L, Han KH, et al. Continued participation in a 10-year tight control treat-to-target study in rheumatoid arthritis: Why keep patients doing their best? Arthritis Care Res (Hoboken). 2015 June;67(6):739–745. doi: 10.1002/acr.22540

Misinformation, fear and not having a trusted partner in the medical sector are just a few of the barriers that prevent patients of color from being adequately represented in research and clinical trials for lupus. Experts and patient advocates addressed how to remove these barriers and more during the 2023 ACR Diversification of Clinical Trials Summit.

As a physician, you need to focus on your patients’ needs. As someone who owns or manages a rheumatology practice, you need to focus on your business’s needs. “This can feel like you’re not only wearing two different hats, but that you also have to be two different people,” says Virginia Fraser, global content specialist,…

Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

Design strategies from a Lupus Research Institute conference

Break Barriers: Engaging Diverse Participants in Clinical Trials for Patients with Lupus

10 Tips for Productive Medical Practice Staff Meetings

Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

Mitigate Risk and Increase Success of Lupus Clinical Trials

Related Articles